Overview

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in depressed subjects.

Phase:

Phase 1

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

AstraZeneca

Collaborators:

University of Manchester
University of Oxford

Treatments:

Ketamine

Criteria

Inclusion Criteria:

- Documented clinical diagnosis meeting criteria from the DSM-IV by structured clinical
interview,major depressive disorder, single episode or recurrent

- Outpatient status at screening and at randomisation

Exclusion Criteria:

- A major depression disorder which has a major impact on the subjects current
psychiatric status

- Subjects not allowed to use mood stabilizers, antidepressants or other antipsychotic
or psychoactive drugs

- Subjects with lifetime history of schizophrenia, bi-polar, psychosis and psychotic
depression